Steven Stein
Chief Tech/Sci/R&D Officer chez INCYTE CORPORATION
Fortune : 6 M $ au 31/03/2024
Profil
Steven H. Stein occupe le poste de Chief Medical Officer & Executive Vice President chez Incyte Corp. Le Dr Stein est également membre du conseil d'administration de Kura Oncology, Inc. Au cours de sa carrière, le Dr Stein a été vice-président de l'oncologie mondiale chez GlaxoSmithKline (New Jersey), SVP-US Clinical Development & Medical Affairs chez Novartis Oncology, Inc. et Senior VP-US Clinical Development & Medical Affair chez Novartis Pharmaceuticals Corp. Le Dr Stein a obtenu un doctorat de l'université de Witwatersrand.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION
0,04% | 14/02/2024 | 97 595 ( 0,04% ) | 6 M $ | 31/03/2024 |
KURA ONCOLOGY, INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Steven Stein
| Sociétés | Poste | Début |
|---|---|---|
| INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 02/03/2015 |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
Anciens postes connus de Steven Stein
| Sociétés | Poste | Fin |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Director/Board Member | 14/02/2024 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/02/2015 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/02/2015 |
| GlaxoSmithKline (New Jersey) | Corporate Officer/Principal | 01/04/2011 |
| KURA ONCOLOGY, INC. | Director/Board Member | - |
Formation de Steven Stein
| University of the Witwatersrand | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| GlaxoSmithKline (New Jersey) | |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
